Potentially Clinically Beneficial Interactions Between Biologically-Based Complementary Medicines and Cancer Treatment: A Systematic Scoping Review
Abstract
Purpose: This scoping review aimed to identify primary studies reporting potentially clinically beneficial interactions between biologically-based complementary medicines (BB-CMs) (e.g., herbs, vitamins, minerals, pre/probiotics etc.) and conventional cancer treatments.
Methods: Following Joanna Briggs scoping review methodology, a comprehensive search was conducted across Scopus, MEDLINE, Web of Science Core Collection, CINAHL, Allied and Complementary Medicine, and Embase databases from their inception to September 20,2024. Two reviewers independently screened the citations. Data were extracted by a single reviewer and verified by another. Results were tabulated and narrated.
Results: Fifty-five studies from 14 countries, involving 4,672 adults, adolescents and children, were included in the review. Study designs varied according to the patient characteristics, treatment types, dosages and durations of use, and comprehensiveness of reporting, including adverse events and declarations. Randomized controlled trials (RCTs) (n=29) were most common, followed by non-RCTs (n=9). Studies mostly focused on digestive tract cancers (n=16), breast cancer (n=11) and lung cancer (n=8). The most frequently investigated conventional cancer treatments were chemotherapy (n=17) and chemotherapy with adjunctive medications (n=8), while the most common BB-CMs were traditional medicine multi-ingredient formulations (n=23), vitamins (n=10), and hormone products/pre/probiotics (n=4). The most frequent beneficial interactions evaluated were survival, treatment response, and symptom relief including side effects from conventional cancer treatment, and quality-of-life.
Conclusions: A broad range of studies have evaluated beneficial interactions between BB-CMs and conventional oncological treatments. Further in-depth reviews of these beneficial interactions, along with more clinical trials are indicated to support evidence-informed decision-making by healthcare providers and people living with cancer.
NOTE: This publication references DBM (The Di Bella Method) in these works:
- N° 36 - Di Bella G. - The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer. Neuro Endocrinol Lett. 2011;32(6):751-762;
- N° 37 - Di Bella G, Madarena M. - Complete objective response of oesophageal squamocellular carcinoma to biological treatment. Neuro Endocrinol Lett. 2009;30(3):312-321;
- N° 38 - Di Bella G, Mascia F, Ricchi A, Colori B. - Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report . Neuro Endocrinol Lett. 2013;34(7):660-668.
See also:
- Official Web Site: The Di Bella Method;
- The Di Bella Method (A Fixed Part - Bromocriptine and/or Cabergoline);
- Prolactin inhibitors in oncology - In vitro, review and in vivo publications;
- Beta-Carotene or β-carotene in Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;
- The Di Bella Method (A Fixed Part - Calcium, 2 grams per day, orally);
- The Di Bella Method (A Variable Part - Clioquinol, 125 μg capsules);
- Melatonin use in cancer patients have started in 1974, when melatonin prepared according to Prof. Di Bella’s formulation [...]. For 11 days was administered to the patient, admitted to the general medical ward at the Maggiore-Pizzardi Hospital in Bologna, very slowly (over approx. 8 hours) and intravenously administered 1000 mg of melatonin for 11 days. During the course of each day, the patient was intravenously administered 4 saline drips of 500 ml, each containing ten 25 mg bottles of freeze-dried melatonin, lasting 2 hours, totaling 1000 mg per day. No other drug of any kind was administered in order to ascertain the effect of the MLT without interference [...]. From Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings (Di Bella's Foundation);
- About Melatonin - In vitro, review and in vivo publications;
- 2013 Jan - Publication: Melatonin anticancer effects: Review (from Di Bella's Foundation);
- 2006 Sep - Publication: Key aspects of melatonin physiology: 30 years of research (from Di Bella's Foundation);
- 1980 Sep - International Symposium on Melatonin: Melatonin: an essential factor for the treatment and recovery from leukemia and cancer (Di Bella's Foundation);
- 2015 Dec - Publication: Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy (from Di Bella's Foundation);
- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;
- The Di Bella Method (A Variable Part - Selenium methonine, 40 μg capsules, twice a day);
- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;
- Publication, 2018 Jul: Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor (from Di Bella's Foundation);
- Publication, 2018 Sep: The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature (from Di Bella's Foundation);
- Publication, 2019 Aug: The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity (from Di Bella's Foundation);
- Publication, 2019 Sep: Effects of Somatostatin and Vitamin C on the Fatty Acid Profile of Breast Cancer Cell Membranes (from Di Bella's Foundation);
- Publication, 2019 Sep: Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes (from Di Bella's Foundation);
- Publication, 2020 Sep: Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives (from Di Bella's Foundation);
- The Di Bella Method (A Fixed Part - Vitamin C/Ascorbic Acid, 2–4 grams, twice a day orally);
- Vitamin D (analogues and/or derivatives) and cancer - In vitro, review and in vivo publications;
The Di Bella's Method: Use of Melatonin since 1974 and pseudo-Metronomic Chemotherapy Cyclophosphamide and/or Hydroxyurea - together with others chemical compounds: the dosage and administration schedule must be individualised for each patient - in several Oncological Pathologies:
- Complete objective response to biological therapy of plurifocal breast carcinoma;
- Pleural Mesothelioma: clinical records on 11 patients treated with Di Bella's Method;
- Malignant pleural mesothelioma, stage T3-T4. Consideration of a case study;
- Neuroblastoma: Complete objective response to biological treatment;
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report;
- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report;
- Oesophageal squamocellular carcinoma: a complete and objective response;
- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;
- Disease Control after Androgen Deprivation Therapy Combined with Di Bella Multitherapy;






